Skip to content

PTSD: all studies

Page 113 of 211: studies 1,121 to 1,130 of 2,101, newest first. Back to the PTSD overview

Research

The effect of mindfulness-based couple-centered intervention in parents following fetal abnormalities requiring pregnancy termination: study protocol for a randomized controlled trial.

BMC Pregnancy and Childbirth October 2, 2025 Shiwen Sun, Jialu Qian, Yaping Sun et al.

BACKGROUND: Termination of pregnancy for fetal abnormalities (TOPFA) represents a significant global healthcare challenge. In China, the occurrence of fetal abnormalities is notably high. TOPFA is a devastating traumatic event for parents and families. Parents frequently encounter psychological issues and negative emotions such as depression, anxiety, prolonged grief, feelings of inadequacy,...

Nonrandomized Open Trial of a Mindfulness- and Compassion-Based Selective Preventive Mobile Health Intervention for Forcibly Displaced People.

Mindfulness October 2, 2025 Shani Zohar Puris, Kim Yuval, Gebreyohans Gebremariam et al.

This study tested the feasibility of Mindfulness-SOS for Refugees, a novel lay- and minimally guided mobile health mindfulness- and compassion-based intervention, that is trauma-sensitive and socio-culturally adapted for diverse forcibly displaced people. A pre-registered, nonrandomized, single-arm, open-trial of Mindfulness-SOS as a selective preventive intervention was conducted during the...

DOI: 10.1007/s12671-025-02675-9 (opens in new tab) Full text (opens in new tab) Covid-19 Forcibly displaced people Mobile health

Psychedelika assistierte Therapie

Psychotherapie-Wissenschaft October 1, 2025 Heiner Dörfler

Die psychedelika assistierte Psychotherapie erfährt aktuell eine wissenschaftlich fundierte Renaissance. Studien zeigen eine therapeutische Wirksamkeit von Substanzen wie Psilocybin, LSD und MDMA bei verschiedenen psychischen Störungsbildern, insbesondere bei therapieresistenter Depression, PTBS, Angstund Suchterkrankungen. In der Schweiz nimmt diese Entwicklung eine besondere Stellung ein: Als...

DOI: 10.30820/1664-9583-2025-2-7 (opens in new tab) Chronic disease Butyrophenone Continuing education Gynecology

Preparing Social Work for Psychedelic-Assisted Therapy.

Social Work October 1, 2025 Heidi L Allen, Brooke L Stott

With MDMA, LSD, and psilocybin receiving “Breakthrough Therapy” designation by the U.S. Food and Drug Administration (FDA) and moving into Phase 3 clinical trials, we are closer than ever to legal administration of these compounds for mental health treatment. Research from Lykos, Usona Institute, Mindmed, Compass Pathways, and Johns Hopkins, among others, has shown promising efficacy of the...

Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders

Therapeutic Advances in Psychopharmacology October 1, 2025 Luke Flynn, Martin Krsak, Mary Rondeau et al.

Background: Job-related stress and its extreme form, burnout, continue to affect almost half of all frontline healthcare workers and first responders. Current treatments are inadequate. Objectives: To evaluate a model of ketamine-assisted psychotherapy (KAP) delivered in a group format to address symptoms of anxiety, depression, trauma, and burnout via repeated measures of the Generalized...

DOI: 10.1177/20451253251383415 (opens in new tab) Health care Stress reduction Intervention counseling Stress linguistics +7

The evidence for ketamine treatment in older adults with psychiatric illness: a scoping review

Therapeutic Advances in Chronic Disease October 1, 2025 Kayla Murphy, Julia C. Golden, Haley Schuster et al. 3 citations

Background: Ketamine, an N-methyl-D-aspartate antagonist, has been used for decades as an anesthetic agent, but more recently it has been studied in psychiatric illness. Though ketamine has been investigated for use in the general population, fewer studies have investigated the efficacy and tolerability of this treatment for older (age >60) adults. Objectives: This review sought to compile the...

Ayahuasca: Pharmacological Composition and Potential Benefits

Research Journal of Pharmacy and Technology October 1, 2025 Raj Nashikkar, Shrikrishna Baokar, Rajendra Patil

Ayahuasca is a traditional hallucinogenic concoction utilised by indigenous populations in the Amazon Basin for ages in spiritual and therapeutic rituals. The increasing global popularity is attributed to its alleged medicinal and consciousness-expanding properties. The infusion is primarily composed of two key components: the Banisteriopsis caapi vine and the leaves of Psychotria viridis,...

The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry.

Journal of Personalized Medicine September 28, 2025 Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu et al. 2 citations

Psychedelic compounds are gaining renewed attention across disciplines for their profound psychological and neurobiological effects. Emerging research highlights their efficacy in treating mood disorders, PTSD, and addiction by enhancing neuroplasticity and disrupting maladaptive cognitive patterns. From a psychological standpoint, psychedelics facilitate introspection, emotional processing,...

Overview of Ketamine Guidelines in Psychiatric Disorders

International Journal of Psychiatry September 26, 2025 Hesham Maged Mohamed Abdelfatah, Mahmoud Mohamed Gomaa

Ketamine has anti depressive characters and approved by (FDA) for the induction and maintenance of anesthesia, Ketamine has been incorporated into the management of psychiatric disorders, such as Major Depressive Disorder (MDD) especially with suicidal ideation or attempting, and of label in management of Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder...

Recreational MDMA use in Norway: results from an internet convenience sample.

Frontiers in Psychiatry September 26, 2025 Cato Grønnerød, Thea Rønningen, Ingrid Rike Haugsjå et al.

The purpose of the article: In recent years, a renewed interest has emerged in investigating the use of MDMA in the treatment of mental disorders. However, knowledge about the characteristics of recreational use of MDMA, its contexts and effects are limited. Methods: We recruited adult Norwegian participants aged 18 to 65 who reported having had a memorable experience after using MDMA. They...

DOI: 10.3389/fpsyt.2025.1619676 (opens in new tab) Full text (opens in new tab) Ecstasy consumption Molly usage Recreational MDMA Use Drug taking +21